Nutritional intervention as adjuvant therapy for T-cell acute lymphoblastic leukemia

Affiliations

¹ Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.

Comment

Miriam B Garcia et al. Blood Adv. 2024.

. 2024 Oct 22;8(20):5266-5267.

doi: 10.1182/bloodadvances.2024013607.

¹ Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials.
Shimony S, Flamand Y, Valtis YK, Place AE, Silverman LB, Vrooman LM, Brunner AM, Sallan SE, Stone RM, Wadleigh M, Neuberg DS, DeAngelo DJ, Luskin MR. Shimony S, et al. Blood Adv. 2023 Sep 26;7(18):5234-5245. doi: 10.1182/bloodadvances.2023009976. Blood Adv. 2023. PMID: 37432068 Free PMC article.

1. Shimony S, Flamand Y, Valtis YK, et al. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023;7(18):5234–5245. - PMC - PubMed
1. Wadhwa A, Chen Y, Hageman L, et al. Body mass index during maintenance therapy and relapse risk in children with acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2023;129(1):151–160. - PMC - PubMed
1. Orgel E, Sea JL, Mittelman SD. Mechanisms by which obesity impacts survival from acute lymphoblastic leukemia. J Natl Cancer Inst Monogr. 2019;2019(54):152–156. - PMC - PubMed
1. Egnell C, Heyman M, Jonsson OG, et al. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia. Br J Haematol. 2022;196(5):1239–1247. - PubMed
1. Orgel E, Framson C, Buxton R, et al. Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial. Blood Adv. 2021;5(7):1853–1861. - PMC - PubMed